Advancing regenerative
medicine Targeting Myocardial Infarction
& Heart Failure

HIGHLIGHTS

1 / 5

                                Pig Studies confirm that FSTL1 treatment results in 50% scar
                                  reduction and up to 75% recovery of heart function after
                                  myocardial infarction
                              

HIGHLIGHTS

2 / 5

Awarded US patent covering pharmaceutical compositions of FSTL1

HIGHLIGHTS

3 / 5

Awarded NIH SBIR Grant $4.2 M (R&D Diabetic population)

HIGHLIGHTS

4 / 5

                                Awarded The Global Health & Pharma Biotechnology Awards 2021,
                                  for second year in a row

HIGHLIGHTS

5 / 5

Regencor appoints Nodes as exclusive advisors

Myocardial Regeneration
The ultimate goal of clinical cardiology

Regencor's team envisions a future where myocardial infarctions no longer impose incurable & life threatening tissue damage or progression to heart failure

Subcutaneous Sustained Delivery via Pump: A true game-changer in heart disease therapy

Our recombinant protein, delivered subcutaneously, reverses the formation of scar tissue. Scar tissue is the most serious complication after a myocardial infarction as it weakens the heart and leads to progressive heart failure.

Learn more about OUR TECHNOLOGY